Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Debt (2016)

Gyre Therapeutics (GYRE) has disclosed Total Debt for 7 consecutive years, with $28000.0 as the latest value for Q3 2016.

  • On a quarterly basis, Total Debt fell 95.86% to $28000.0 in Q3 2016 year-over-year; TTM through Sep 2016 was $28000.0, a 95.86% decrease, with the full-year FY2015 number at $1.2 million, changed N/A from a year prior.
  • Total Debt was $28000.0 for Q3 2016 at Gyre Therapeutics, down from $130000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $2.7 million in Q1 2012 to a low of $28000.0 in Q3 2016.
  • A 5-year average of $1.2 million and a median of $1.1 million in 2013 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: skyrocketed 41.42% in 2015, then crashed 95.86% in 2016.
  • Gyre Therapeutics' Total Debt stood at $2.0 million in 2012, then plummeted by 42.83% to $1.1 million in 2013, then crashed by 57.92% to $478000.0 in 2014, then skyrocketed by 141.84% to $1.2 million in 2015, then plummeted by 97.58% to $28000.0 in 2016.
  • Per Business Quant, the three most recent readings for GYRE's Total Debt are $28000.0 (Q3 2016), $130000.0 (Q2 2016), and $196000.0 (Q1 2016).